The main point I was trying to make about the unblinding of data relating to efficacy from the DARRT-2 trial was to do with controlling the type I error rate. Although it is an adaptive Phase2/3 trial, I presume NOX will still need to control the type I error rate if they choose to unblind the data in order to provide confirmatory evidence of efficacy at the final analysis. Unless NOX expect to make the appropriate adjustments to their sample size and/or treatment selection for the confirmatory trial (as you've mentioned), but NOX hasn't yet made that information public.
I've taken onboard and agree with your comments about the IONIC study.
(20min delay)